RecruitingNot ApplicableNCT07376486

Duodenal pulsENDO as an Early Treatment for Type 2 DM

Duodenal Recellularization Via Electroporation Therapy as an Early Treatment for Type 2 Diabetes Mellitus (DREAM-1 Study)

Sponsor

Chinese University of Hong Kong

Enrollment

40 participants

Start Date

Sep 1, 2026

Study Type

INTERVENTIONAL

Conditions

Diabete Mellitus T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Summary

This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called pulsENDO treatment for people with diabete mellitus and t2 diabetes and fatty liver disease (non-alcoholic origin). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREpulsENDO treatment

The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.